San Diego biotech lays off nearly all its staff after drug trial failure and 2 patient deaths
Source ↗
👁 0
💬 0
San Diego biotech Artiva Biotherapeutics is laying off about 94% of its workforce and abandoning its lead immunotherapy treatment for rheumatoid arthritis roughly five months after raising about $300 million from investors.
The company said Tuesday that updated data showed its lead candidate, AlloNK — an off-the-shelf natural killer cell therapy — was initially effective in clinical trials, but the benefits did not last long enough to justify a planned Phase 3 trial. The biotech also faced scrut
The company said Tuesday that updated data showed its lead candidate, AlloNK — an off-the-shelf natural killer cell therapy — was initially effective in clinical trials, but the benefits did not last long enough to justify a planned Phase 3 trial. The biotech also faced scrut
Comments (0)